A detailed history of Headlands Technologies LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Headlands Technologies LLC holds 12,052 shares of RARE stock, worth $567,890. This represents 0.08% of its overall portfolio holdings.

Number of Shares
12,052
Previous 6,124 96.8%
Holding current value
$567,890
Previous $251,000 166.53%
% of portfolio
0.08%
Previous 0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.21 - $59.36 $238,364 - $351,886
5,928 Added 96.8%
12,052 $669,000
Q2 2024

Aug 07, 2024

BUY
$37.42 - $51.61 $206,932 - $285,403
5,530 Added 930.98%
6,124 $251,000
Q1 2024

May 07, 2024

BUY
$43.02 - $53.69 $25,553 - $31,891
594 New
594 $27,000
Q3 2023

Nov 09, 2023

BUY
$34.92 - $46.66 $39,354 - $52,585
1,127 Added 50.67%
3,351 $119,000
Q2 2023

Aug 03, 2023

BUY
$37.35 - $52.15 $81,647 - $113,999
2,186 Added 5752.63%
2,224 $102,000
Q1 2023

May 01, 2023

BUY
$36.99 - $48.71 $1,405 - $1,850
38 New
38 $1,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.3B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.